Kosmonova buran
Top-News
hi LUCID
Beiträge:
48
Zugriffe: 16.903 / Heute: 2
Zugriffe: 16.903 / Heute: 2
|
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI USA Banks UCITS ETF 1D
Perf. 12M: +70,66%
Xtrackers LevDAX Daily Swap UCITS ETF 1C
Perf. 12M: +59,80%
Xtrackers MSCI Pakistan Swap UCITS ETF 1C
Perf. 12M: +52,93%
Xtrackers MSCI China UCITS ETF 1D
Perf. 12M: +46,29%
Xtrackers MSCI China UCITS ETF 1C
Perf. 12M: +45,84%
:::::::::::::::::: 0,66 $ +20,00% +0,11 $
In Euro: 0,4880 € | Nasdaq OTC BB, 13.06.14:::::: und SCHICK
In Euro: 0,4880 € | Nasdaq OTC BB, 13.06.14:::::: und SCHICK
Datum Erster Hoch Tief Schluss Stücke Volumen
17.06.14 0,66 0,66§0,60 0,60 $ 9.200 5.952
GrB
17.06.14 0,66 0,66§0,60 0,60 $ 9.200 5.952
GrB
::::::::::::::::::::::: 0,67 $ +11,67% +0,07 $
In Euro: 0,4923 € | Nasdaq OTC BB, 19.06.14:::::: ..::hopshopshopshops HALLO
In Euro: 0,4923 € | Nasdaq OTC BB, 19.06.14:::::: ..::hopshopshopshops HALLO
Datum Erster Hoch Tief Schluss Stücke Volumen
20.06.14 0,67 0,67§0,67 0,67 $ 1.300 871
GrB
20.06.14 0,67 0,67§0,67 0,67 $ 1.300 871
GrB
www.caliberid.com/investor-presentations.html GrB
NASD OTCQB
LCDX - Common Stock Ticker
LCDXW - Common Stock Warrants Ticker
www.caliberid.com/stockholder-info.html
LCDX - Common Stock Ticker
LCDXW - Common Stock Warrants Ticker
www.caliberid.com/stockholder-info.html
Common Stock & Common Stock Warrants
American Stock Transfer & Trust Company
(800) 937-5449
www.amstock.com
www.caliberid.com/stockholder-info.html
American Stock Transfer & Trust Company
(800) 937-5449
www.amstock.com
www.caliberid.com/stockholder-info.html
Marcum LLP
Boston, Massachusetts
www.caliberid.com/stockholder-info.html
Boston, Massachusetts
www.caliberid.com/stockholder-info.html
Caliber Imaging & Diagnostics
Attn: Richard C. Christopher, Chief Financial Officer
10 Post Office Square North Tower, 11th Floor – Suite 1150
Boston, MA 02109
(617) 348-9821
rchristopher@caliberid.com
www.caliberid.com/stockholder-info.html
Attn: Richard C. Christopher, Chief Financial Officer
10 Post Office Square North Tower, 11th Floor – Suite 1150
Boston, MA 02109
(617) 348-9821
rchristopher@caliberid.com
www.caliberid.com/stockholder-info.html
Raymond C. Zemlin, Secretary
Goodwin Procter LLP
Richard C. Christopher, Asst. Secretary
Chief Financial Officer, Caliber I.D.
www.caliberid.com/stockholder-info.html
Goodwin Procter LLP
Richard C. Christopher, Asst. Secretary
Chief Financial Officer, Caliber I.D.
www.caliberid.com/stockholder-info.html
Guidelines have been adopted by the Board of Directors to assist in the exercise of its responsibilities consistent with the rules of applicable law. These Guidelines reflect the Board's commitment to monitor the effectiveness of policy and decision making both at the Board and management level, with a view to building long-term value for Caliber I.D.'s stockholders.www.caliberid.com/corporategovernance.html
www.caliberid.com/corporategovernance.html GrB
50 Methodist Hill Drive Suite 1000
Rochester, NY 14623
Phone: 585-239-9800
Fax: 585-239-9806
www.caliberid.com/contact.html
Rochester, NY 14623
Phone: 585-239-9800
Fax: 585-239-9806
www.caliberid.com/contact.html
VivaScan™ Non-Invasive ‘Optical Biopsy’ Comes to Beverly Hills’ NIDIskin Consulting
Posted on June 9, 2014 by Caliber I.D.
Dr. Babar Rao, World-Renowned Dermatologist, Performs the VivaScan to Assess Skin Lesions
BEVERLY HILLS, CA – June 9, 2014 – Many people are worried about the appearance of a mole or other lesion on their skin. Those who live in California now have a new option at their disposal: VivaScan™, a new procedure being offered at NIDIskin (Non-Invasive Diagnostic Imaging of the Skin) Consulting, located at 8383 Wilshire Boulevard in Beverly Hills, California.
VivaScan is a safe, non-invasive imaging procedure that obtains cellular images of the skin, which can then be analyzed by a physician to make a diagnosis and decide on treatment. Using a handheld confocal microscope, VivaScan produces clear, microscopic images that reveal a level of detail that is equivalent to analyzing a skin tissue sample in a laboratory. Because VivaScan is completely non-invasive and does not damage the skin by removing the tissue from the body the way a biopsy does, it can make unlimited repeat scans of the same area over time.
Babar K. Rao, M.D., Director of NIDIskin Consulting and a confocal pathologist, said, “There is no question that early skin cancer screening can have an impact on treatment outcomes. Yet patients often put off or avoid regular skin checks because they are afraid of needing a biopsy, especially one that might result in a benign diagnosis and turn out to have been unnecessary. VivaScan allows me to determine immediately which moles or spots actually require removal, without any unnecessary biopsies or scarring.”
VivaScan, which was developed by Caliber Imaging & Diagnostics (Caliber I.D.), can take cellular level images of entire lesions, layer by layer, at and below the surface of the skin, and can help physicians diagnose most skin diseases and disorders. Since there is no cutting involved, there is also no possibility of infection or scarring. Obtaining an image takes just a few minutes. A qualified doctor can make a determination at the bedside, or the image can be diagnosed remotely through Caliber I.D.’s VivaNet® Telepathology system.
L. Michael Hone, Chief Executive Officer of Caliber I.D., said, “Skin cancer is the most prevalent cancer in the United States, with an estimated 3.5 million new cases each year. Until recently, the only way to diagnose this condition was by visual inspection, followed by an invasive and painful biopsy of suspect areas were found. Laboratory results could take days, and visible areas of the skin could be scarred. Clearly, there is a significant need for a more accurate, less invasive way to assess skin cancers and benign lesions. We believe VivaScan offers this option to the general public on a large scale for the very first time.”
For more information about VivaScan, please visit caliberid.com/vivascan.html, or NIDIskin Consulting at www.nidiskin.com/
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics’ proprietary, cutting-edge VivaScope® system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope has the potential to significantly improve outcomes and reduce costs. The VivaScan™ procedure, which utilizes the VivaScope for dermatological examination, allows physicians to detect cancerous lesions that appear benign, and reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the academic, medical and therapeutic research markets. For more information about Caliber I.D. and its products, please visit www.caliberid.com.
VivaScope® and VivaNet® are registered trademarks of Caliber Imaging & Diagnostics.
VivaScan™ is a trademark of Caliber Imaging and Diagnostics.
Safe Harbor
This press release contains “forward looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including the statements regarding the potential for future product revenue growth and financial performance. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.
Contact:
Company Contact:
Richard Christopher
Chief Financial Officer
(617) 348-9821
rchristopher@caliberid.com
Investor Relations Contact:
LHA
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
Public Relations Contacts:
Dian Griesel Int’l.
Susan Forman or Laura Radocaj
(212) 825-3210
sforman@dgicomm.com
lradocaj@dgicomm.comwww.caliberid.com/pressreleases/?p=297#more-297
Posted on June 9, 2014 by Caliber I.D.
Dr. Babar Rao, World-Renowned Dermatologist, Performs the VivaScan to Assess Skin Lesions
BEVERLY HILLS, CA – June 9, 2014 – Many people are worried about the appearance of a mole or other lesion on their skin. Those who live in California now have a new option at their disposal: VivaScan™, a new procedure being offered at NIDIskin (Non-Invasive Diagnostic Imaging of the Skin) Consulting, located at 8383 Wilshire Boulevard in Beverly Hills, California.
VivaScan is a safe, non-invasive imaging procedure that obtains cellular images of the skin, which can then be analyzed by a physician to make a diagnosis and decide on treatment. Using a handheld confocal microscope, VivaScan produces clear, microscopic images that reveal a level of detail that is equivalent to analyzing a skin tissue sample in a laboratory. Because VivaScan is completely non-invasive and does not damage the skin by removing the tissue from the body the way a biopsy does, it can make unlimited repeat scans of the same area over time.
Babar K. Rao, M.D., Director of NIDIskin Consulting and a confocal pathologist, said, “There is no question that early skin cancer screening can have an impact on treatment outcomes. Yet patients often put off or avoid regular skin checks because they are afraid of needing a biopsy, especially one that might result in a benign diagnosis and turn out to have been unnecessary. VivaScan allows me to determine immediately which moles or spots actually require removal, without any unnecessary biopsies or scarring.”
VivaScan, which was developed by Caliber Imaging & Diagnostics (Caliber I.D.), can take cellular level images of entire lesions, layer by layer, at and below the surface of the skin, and can help physicians diagnose most skin diseases and disorders. Since there is no cutting involved, there is also no possibility of infection or scarring. Obtaining an image takes just a few minutes. A qualified doctor can make a determination at the bedside, or the image can be diagnosed remotely through Caliber I.D.’s VivaNet® Telepathology system.
L. Michael Hone, Chief Executive Officer of Caliber I.D., said, “Skin cancer is the most prevalent cancer in the United States, with an estimated 3.5 million new cases each year. Until recently, the only way to diagnose this condition was by visual inspection, followed by an invasive and painful biopsy of suspect areas were found. Laboratory results could take days, and visible areas of the skin could be scarred. Clearly, there is a significant need for a more accurate, less invasive way to assess skin cancers and benign lesions. We believe VivaScan offers this option to the general public on a large scale for the very first time.”
For more information about VivaScan, please visit caliberid.com/vivascan.html, or NIDIskin Consulting at www.nidiskin.com/
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics’ proprietary, cutting-edge VivaScope® system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope has the potential to significantly improve outcomes and reduce costs. The VivaScan™ procedure, which utilizes the VivaScope for dermatological examination, allows physicians to detect cancerous lesions that appear benign, and reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the academic, medical and therapeutic research markets. For more information about Caliber I.D. and its products, please visit www.caliberid.com.
VivaScope® and VivaNet® are registered trademarks of Caliber Imaging & Diagnostics.
VivaScan™ is a trademark of Caliber Imaging and Diagnostics.
Safe Harbor
This press release contains “forward looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including the statements regarding the potential for future product revenue growth and financial performance. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.
Contact:
Company Contact:
Richard Christopher
Chief Financial Officer
(617) 348-9821
rchristopher@caliberid.com
Investor Relations Contact:
LHA
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
Public Relations Contacts:
Dian Griesel Int’l.
Susan Forman or Laura Radocaj
(212) 825-3210
sforman@dgicomm.com
lradocaj@dgicomm.comwww.caliberid.com/pressreleases/?p=297#more-297
VivaScan™ Non-Invasive ‘Optical Biopsy’ Comes to Beverly Hills’ NIDIskin Consulting
Posted on June 9, 2014 by Caliber I.D.
Dr. Babar Rao, World-Renowned Dermatologist, Performs the VivaScan to Assess Skin Lesions
BEVERLY HILLS, CA – June 9, 2014 – Many people are worried about the appearance of a mole or other lesion on their skin. Those who live in California now have a new option at their disposal: VivaScan™, a new procedure being offered at NIDIskin (Non-Invasive Diagnostic Imaging of the Skin) Consulting, located at 8383 Wilshire Boulevard in Beverly Hills, California.
VivaScan is a safe, non-invasive imaging procedure that obtains cellular images of the skin, which can then be analyzed by a physician to make a diagnosis and decide on treatment. Using a handheld confocal microscope, VivaScan produces clear, microscopic images that reveal a level of detail that is equivalent to analyzing a skin tissue sample in a laboratory. Because VivaScan is completely non-invasive and does not damage the skin by removing the tissue from the body the way a biopsy does, it can make unlimited repeat scans of the same area over time.
Babar K. Rao, M.D., Director of NIDIskin Consulting and a confocal pathologist, said, “There is no question that early skin cancer screening can have an impact on treatment outcomes. Yet patients often put off or avoid regular skin checks because they are afraid of needing a biopsy, especially one that might result in a benign diagnosis and turn out to have been unnecessary. VivaScan allows me to determine immediately which moles or spots actually require removal, without any unnecessary biopsies or scarring.”
VivaScan, which was developed by Caliber Imaging & Diagnostics (Caliber I.D.), can take cellular level images of entire lesions, layer by layer, at and below the surface of the skin, and can help physicians diagnose most skin diseases and disorders. Since there is no cutting involved, there is also no possibility of infection or scarring. Obtaining an image takes just a few minutes. A qualified doctor can make a determination at the bedside, or the image can be diagnosed remotely through Caliber I.D.’s VivaNet® Telepathology system.
L. Michael Hone, Chief Executive Officer of Caliber I.D., said, “Skin cancer is the most prevalent cancer in the United States, with an estimated 3.5 million new cases each year. Until recently, the only way to diagnose this condition was by visual inspection, followed by an invasive and painful biopsy of suspect areas were found. Laboratory results could take days, and visible areas of the skin could be scarred. Clearly, there is a significant need for a more accurate, less invasive way to assess skin cancers and benign lesions. We believe VivaScan offers this option to the general public on a large scale for the very first time.”
For more information about VivaScan, please visit caliberid.com/vivascan.html, or NIDIskin Consulting at www.nidiskin.com/
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics’ proprietary, cutting-edge VivaScope® system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope has the potential to significantly improve outcomes and reduce costs. The VivaScan™ procedure, which utilizes the VivaScope for dermatological examination, allows physicians to detect cancerous lesions that appear benign, and reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the academic, medical and therapeutic research markets. For more information about Caliber I.D. and its products, please visit www.caliberid.com.
VivaScope® and VivaNet® are registered trademarks of Caliber Imaging & Diagnostics.
VivaScan™ is a trademark of Caliber Imaging and Diagnostics.
Safe Harbor
This press release contains “forward looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including the statements regarding the potential for future product revenue growth and financial performance. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.
Contact:
Company Contact:
Richard Christopher
Chief Financial Officer
(617) 348-9821
rchristopher@caliberid.com
Investor Relations Contact:
LHA
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
Public Relations Contacts:
Dian Griesel Int’l.
Susan Forman or Laura Radocaj
(212) 825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com
www.caliberid.com/pressreleases/?p=297
Posted on June 9, 2014 by Caliber I.D.
Dr. Babar Rao, World-Renowned Dermatologist, Performs the VivaScan to Assess Skin Lesions
BEVERLY HILLS, CA – June 9, 2014 – Many people are worried about the appearance of a mole or other lesion on their skin. Those who live in California now have a new option at their disposal: VivaScan™, a new procedure being offered at NIDIskin (Non-Invasive Diagnostic Imaging of the Skin) Consulting, located at 8383 Wilshire Boulevard in Beverly Hills, California.
VivaScan is a safe, non-invasive imaging procedure that obtains cellular images of the skin, which can then be analyzed by a physician to make a diagnosis and decide on treatment. Using a handheld confocal microscope, VivaScan produces clear, microscopic images that reveal a level of detail that is equivalent to analyzing a skin tissue sample in a laboratory. Because VivaScan is completely non-invasive and does not damage the skin by removing the tissue from the body the way a biopsy does, it can make unlimited repeat scans of the same area over time.
Babar K. Rao, M.D., Director of NIDIskin Consulting and a confocal pathologist, said, “There is no question that early skin cancer screening can have an impact on treatment outcomes. Yet patients often put off or avoid regular skin checks because they are afraid of needing a biopsy, especially one that might result in a benign diagnosis and turn out to have been unnecessary. VivaScan allows me to determine immediately which moles or spots actually require removal, without any unnecessary biopsies or scarring.”
VivaScan, which was developed by Caliber Imaging & Diagnostics (Caliber I.D.), can take cellular level images of entire lesions, layer by layer, at and below the surface of the skin, and can help physicians diagnose most skin diseases and disorders. Since there is no cutting involved, there is also no possibility of infection or scarring. Obtaining an image takes just a few minutes. A qualified doctor can make a determination at the bedside, or the image can be diagnosed remotely through Caliber I.D.’s VivaNet® Telepathology system.
L. Michael Hone, Chief Executive Officer of Caliber I.D., said, “Skin cancer is the most prevalent cancer in the United States, with an estimated 3.5 million new cases each year. Until recently, the only way to diagnose this condition was by visual inspection, followed by an invasive and painful biopsy of suspect areas were found. Laboratory results could take days, and visible areas of the skin could be scarred. Clearly, there is a significant need for a more accurate, less invasive way to assess skin cancers and benign lesions. We believe VivaScan offers this option to the general public on a large scale for the very first time.”
For more information about VivaScan, please visit caliberid.com/vivascan.html, or NIDIskin Consulting at www.nidiskin.com/
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics’ proprietary, cutting-edge VivaScope® system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope has the potential to significantly improve outcomes and reduce costs. The VivaScan™ procedure, which utilizes the VivaScope for dermatological examination, allows physicians to detect cancerous lesions that appear benign, and reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the academic, medical and therapeutic research markets. For more information about Caliber I.D. and its products, please visit www.caliberid.com.
VivaScope® and VivaNet® are registered trademarks of Caliber Imaging & Diagnostics.
VivaScan™ is a trademark of Caliber Imaging and Diagnostics.
Safe Harbor
This press release contains “forward looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including the statements regarding the potential for future product revenue growth and financial performance. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.
Contact:
Company Contact:
Richard Christopher
Chief Financial Officer
(617) 348-9821
rchristopher@caliberid.com
Investor Relations Contact:
LHA
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
Public Relations Contacts:
Dian Griesel Int’l.
Susan Forman or Laura Radocaj
(212) 825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com
www.caliberid.com/pressreleases/?p=297
— Caliber Imaging & Diagnostics (OTCQB: LCDX), formerly Lucid, Inc., has inaugurated its new VivaScan™ skin imaging procedure for the general public at NIDIskin (Non-Invasive Diagnostic Imaging of the Skin) Consulting, located at 8383 Wilshire Boulevard in Beverly Hills, California.www.caliberid.com/pressreleases/
Caliber Imaging & Diagnostics’ VivaScope® System Featured on Boston’s ABC-TV Affiliate and Ivanhoe Broadcast News
Posted on June 11, 2014 by Caliber I.D.
News Segments and Articles Highlight Advantages of Non-Invasive Biopsy Using VivaScope
BOSTON and ROCHESTER, NY — June 11, 2014 — Caliber Imaging & Diagnostics (OTCQB: LCDX), formerly Lucid, Inc., was featured in two recent media reports.
On May 18, Caliber I.D. was the focus of a news segment on the ABC-TV affiliate in Boston (WCVB-TV) and an accompanying article. The segment, titled “Optical biopsy diagnoses skin cancer without surgery: New biopsy method promises no cutting, no scars,” focuses on the advantages of the Company’s FDA-cleared VivaScope system to perform the VivaScan™ procedure, for diagnosing skin cancer without an invasive biopsy in the majority of cases. During the segment, Dr. Daniel Mark Siegel, clinical professor of dermatology at The State University of New York Health Science Center and a member of Caliber I.D.’s Board of Directors, says, “This is a technology whose time has come… We can look at one surface of the skin and then we can work our way down through deeper layers just like doing a CAT scan of the skin.”
To view the segment and read the article, please visit the following link:
www.wcvb.com/health/...-cancer-without-surgery/25695518#!OKWyt
On June 4, Caliber I.D.’s VivaScope system was the subject of a video segment, online article and Q&A distributed by Ivanhoe Broadcast News, the country’s largest television news-gathering organization covering medical breakthrough stories, discoveries in science and health stories. Ivanhoe has a client base of more than 250 television network affiliates in the United States, reaching 80 million households every day. To date, the segment has been broadcast by WJRT-TV, the ABC affiliate in Flint, MI; WJXT-TV, an independent station in Jacksonville, FL; and ScienceDaily, a consumer website with an average of six million visitors per month.
To read the Ivanhoe article, titled “More VivaScope: Fewer Biopsies,” please visit the following link: www.ivanhoe.com/channels/p_channelstory.cfm?storyid=33340
To read a research summary of the Ivanhoe article, please visit the following link: www.ivanhoe.com/channels/...yid=33341&channelid=CHAN-10001
To read a Q&A Ivanhoe conducted about VivaScope with Babar K. Rao, MD, of the Department of Dermatology at Rutgers’ Robert Wood Johnson Medical School, please visit the following link:www.ivanhoe.com/channels/...yid=33342&channelid=CHAN-10001
To view the Ivanhoe video segment in its entirety, please visit the following link:
www.sciencedaily.com/videos/...88433aca70691530d531c659929.htm
The videos at the links above are provided for informational purposes only. Caliber Imaging & Diagnostics is not responsible for the content of the linked videos.
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics’ proprietary, cutting-edge VivaScope® system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope has the potential to significantly improve outcomes and reduce costs. The VivaScan™ procedure, which utilizes the VivaScope for dermatological examination, allows physicians to detect cancerous lesions that appear benign, and reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the academic, medical and therapeutic research markets. For more information about Caliber I.D. and its products, please visit www.caliberid.com.
VivaScope® is a registered trademark of Caliber Imaging & Diagnostics.
VivaScan™ is a trademark of Caliber Imaging and Diagnostics
Safe Harbor
This press release contains “forward looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including the statements regarding the potential for future product revenue growth and financial performance. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.
Contact:
Caliber Imaging & Diagnostics
Richard Christopher
Chief Financial Officer
(617) 348-9821
rchristopher@caliberid.com
or
Dian Griesel Int’l.
Susan Forman or Laura Radocaj
(212) 825-3210
sforman@dgicomm.com
lradocaj@dgicomm.comwww.caliberid.com/pressreleases/?p=313
Posted on June 11, 2014 by Caliber I.D.
News Segments and Articles Highlight Advantages of Non-Invasive Biopsy Using VivaScope
BOSTON and ROCHESTER, NY — June 11, 2014 — Caliber Imaging & Diagnostics (OTCQB: LCDX), formerly Lucid, Inc., was featured in two recent media reports.
On May 18, Caliber I.D. was the focus of a news segment on the ABC-TV affiliate in Boston (WCVB-TV) and an accompanying article. The segment, titled “Optical biopsy diagnoses skin cancer without surgery: New biopsy method promises no cutting, no scars,” focuses on the advantages of the Company’s FDA-cleared VivaScope system to perform the VivaScan™ procedure, for diagnosing skin cancer without an invasive biopsy in the majority of cases. During the segment, Dr. Daniel Mark Siegel, clinical professor of dermatology at The State University of New York Health Science Center and a member of Caliber I.D.’s Board of Directors, says, “This is a technology whose time has come… We can look at one surface of the skin and then we can work our way down through deeper layers just like doing a CAT scan of the skin.”
To view the segment and read the article, please visit the following link:
www.wcvb.com/health/...-cancer-without-surgery/25695518#!OKWyt
On June 4, Caliber I.D.’s VivaScope system was the subject of a video segment, online article and Q&A distributed by Ivanhoe Broadcast News, the country’s largest television news-gathering organization covering medical breakthrough stories, discoveries in science and health stories. Ivanhoe has a client base of more than 250 television network affiliates in the United States, reaching 80 million households every day. To date, the segment has been broadcast by WJRT-TV, the ABC affiliate in Flint, MI; WJXT-TV, an independent station in Jacksonville, FL; and ScienceDaily, a consumer website with an average of six million visitors per month.
To read the Ivanhoe article, titled “More VivaScope: Fewer Biopsies,” please visit the following link: www.ivanhoe.com/channels/p_channelstory.cfm?storyid=33340
To read a research summary of the Ivanhoe article, please visit the following link: www.ivanhoe.com/channels/...yid=33341&channelid=CHAN-10001
To read a Q&A Ivanhoe conducted about VivaScope with Babar K. Rao, MD, of the Department of Dermatology at Rutgers’ Robert Wood Johnson Medical School, please visit the following link:www.ivanhoe.com/channels/...yid=33342&channelid=CHAN-10001
To view the Ivanhoe video segment in its entirety, please visit the following link:
www.sciencedaily.com/videos/...88433aca70691530d531c659929.htm
The videos at the links above are provided for informational purposes only. Caliber Imaging & Diagnostics is not responsible for the content of the linked videos.
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics’ proprietary, cutting-edge VivaScope® system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued and pending patents worldwide, VivaScope has the potential to significantly improve outcomes and reduce costs. The VivaScan™ procedure, which utilizes the VivaScope for dermatological examination, allows physicians to detect cancerous lesions that appear benign, and reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the academic, medical and therapeutic research markets. For more information about Caliber I.D. and its products, please visit www.caliberid.com.
VivaScope® is a registered trademark of Caliber Imaging & Diagnostics.
VivaScan™ is a trademark of Caliber Imaging and Diagnostics
Safe Harbor
This press release contains “forward looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including the statements regarding the potential for future product revenue growth and financial performance. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.
Contact:
Caliber Imaging & Diagnostics
Richard Christopher
Chief Financial Officer
(617) 348-9821
rchristopher@caliberid.com
or
Dian Griesel Int’l.
Susan Forman or Laura Radocaj
(212) 825-3210
sforman@dgicomm.com
lradocaj@dgicomm.comwww.caliberid.com/pressreleases/?p=313
At Caliber I.D., we are acting on an ambitious strategy to establish ourselves as the leader in cellular resolution in vivo imaging.
Our Rapid Cell Imaging and Diagnosis (Rapid Cell ID) technology and VivaScope® line of cellular imaging products have the potential to influence all medical sectors and specialties in which biopsies are performed. Our Caliber I.D. VivaNet® telepathology platform links attending physicians with remote specialists, allowing near real-time collaborations between medical specialists—saving time, reducing costs, and improving patient outcomes.www.caliberid.com/mission.html
Our Rapid Cell Imaging and Diagnosis (Rapid Cell ID) technology and VivaScope® line of cellular imaging products have the potential to influence all medical sectors and specialties in which biopsies are performed. Our Caliber I.D. VivaNet® telepathology platform links attending physicians with remote specialists, allowing near real-time collaborations between medical specialists—saving time, reducing costs, and improving patient outcomes.www.caliberid.com/mission.html
We initially targeted premier academic institutions in the field of dermatology to establish a solid base of clinical validation in that specialty. The resulting robust library of published clinical evidence supports wider use of the imaging technology.
Moving forward we are focused on:
Extending commercialization to cancer centers and community hospitals and clinics around the world
Building strong partnerships with highly experienced distribution channels in Europe, China, Australia and Brazil
Expanding a strong direct sales team.
Companies & research institutions doing skin care product development.
Convinced that each care specialty represented in hospitals is a springboard for growth, our R&D team continues to:
Adapt our core imaging technologies to fulfill physicians’ needs in other fields of medicine
Exploring the adaptation of the imaging technology to therapeutic technologies
Collaborate with leaders in other specialties such as neurology, head and neck, and gynecology, to build clinical data and accelerate commercializationwww.caliberid.com/mission.html
Moving forward we are focused on:
Extending commercialization to cancer centers and community hospitals and clinics around the world
Building strong partnerships with highly experienced distribution channels in Europe, China, Australia and Brazil
Expanding a strong direct sales team.
Companies & research institutions doing skin care product development.
Convinced that each care specialty represented in hospitals is a springboard for growth, our R&D team continues to:
Adapt our core imaging technologies to fulfill physicians’ needs in other fields of medicine
Exploring the adaptation of the imaging technology to therapeutic technologies
Collaborate with leaders in other specialties such as neurology, head and neck, and gynecology, to build clinical data and accelerate commercializationwww.caliberid.com/mission.html
is a medical technologies company that designs, develops, and markets innovative imaging solutions that shows tissue at the cellular level.
www.caliberid.com/about.html
www.caliberid.com/about.html
and later Lucid, Inc., Caliber Imaging & Diagnostics, Inc. is currently the only company in the world to offer in vivo confocal microscopes designed specifically for imaging skin and other tissue. Caliber I.D.’s Rapid Cell ID technology enables scientists and physicians to characterize intact normal and abnormal cellular architecture that is otherwise invisible to the naked eye.www.caliberid.com/about.html
development by teams in the United States, Europe, and Australia, Caliber I.D. developed the VivaScope, a robust suite of imaging products. The VivaScope® suite offers breakthrough technology that represents a new era in medical imaging. Physicians now have a cellular-level view of the patient's skin at the bedside, allowing for immediate tissue characterization and treatment. For those cases that require additional support from other specialists, Caliber I.D.’s telepathology system allows near real-time collaboration with remote specialists.www.caliberid.com/about.html
Datum Erster Hoch Tief Schluss Stücke Volumen
19.08.14 0,55 0,55§0,55 0,55 $ 2.400 1.320
GrB
19.08.14 0,55 0,55§0,55 0,55 $ 2.400 1.320
GrB
buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…
Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…
Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof
LZB steht für "Landeszentralbank".
http://www.ariva.de/extras/lexikon.m?begriff=LZB
http://www.ariva.de/extras/lexikon.m?begriff=LZB
:::::::::::::: 0,55 $ +3,77% +0,02 $
In Euro: 0,4671 € | Nasdaq OTC Other, 07.01.15 ,GrB
In Euro: 0,4671 € | Nasdaq OTC Other, 07.01.15 ,GrB
Datum Erster Hoch Tief Schluss Stücke Volumen
09.01.15 0,55 0,55§0,55 0,55 $ 500 275
GrB
09.01.15 0,55 0,55§0,55 0,55 $ 500 275
GrB
:::::::::::::: 0,586 $ +17,20% +0,086 $
In Euro: 0,5135 € | Nasdaq OTC Other, 12.02.15::::: Kosmonova buran
In Euro: 0,5135 € | Nasdaq OTC Other, 12.02.15::::: Kosmonova buran
::::::::::::: 0,95 $ +26,67% +0,20 $
In Euro: 0,8502 € | Nasdaq OTC Other, 09.07.15 ,GrB
In Euro: 0,8502 € | Nasdaq OTC Other, 09.07.15 ,GrB
::::::::::: 0,43 $ 0,00% +0,00 $
In Euro: 0,3870 € | 13.06.16 Nasdaq OTC Other ,GrB
In Euro: 0,3870 € | 13.06.16 Nasdaq OTC Other ,GrB
Sandilands & Ewan McNicol, an award winning American and English filmmaking duo who have been working together since 2005. lucidinc.com/
www.boerse-online.de/nachrichten/aktien/...steigen-1027469369
100% ..für was..
hier haben sich wohl ein paar verschaut
hier haben sich wohl ein paar verschaut
Stimmt, ist mir bei meinen Recherchen auch aufgefallen.
Sollten da einige Leute wegen der Namensähnlichkeit gekauft haben, viel Spaß.
Sollten da einige Leute wegen der Namensähnlichkeit gekauft haben, viel Spaß.
von Lucid Motors...!
Das sollte mal gesagt werden.
Das sollte mal gesagt werden.
lasst diesen Thread untergehen
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Caliber Imaging & Diagnostics Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 47 | hi LUCID | buran | Kicky | 27.07.21 12:36 |
